Akero Therapeutics Inc’s recently made public that its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $0.53 million on Jul 16 ’25. In the deal valued at $52.95 per share,10,000 shares were sold. As a result of this transaction, Yale Catriona now holds 91,488 shares worth roughly $4.7 million.
Then, Cheng Andrew sold 30,000 shares, generating $1,534,895 in total proceeds. Upon selling the shares at $51.16, the President and CEO now owns 520,757 shares.
Before that, Rolph Timothy sold 12,500 shares. Akero Therapeutics Inc shares valued at $638,661 were divested by the Chief Scientific Officer at a price of $51.09 per share. As a result of the transaction, Rolph Timothy now holds 167,124 shares, worth roughly $8.59 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -1.34% to $51.38. Over the last five days, the stock has lost -2.56%. Akero Therapeutics Inc shares have risen nearly 89.73% since the year began. Nevertheless, the stocks have risen 84.69% over the past one year.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-06-13, growing by 1.45 million shares to a total of 7.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.3 million shares. There was a rise of 18.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
